TwinStrand Biosciences Announces U.S. Patent And Trademark Office's Patent Trial And Appeal Board Rejects Guardant Health's Challenge To Core Patent Underlying Duplex Sequencing

TwinStrand Biosciences (TwinStrand), the pioneer in Duplex Sequencing® technology, today announced that the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has again rejected Guardant Health, Inc.’s (Nasdaq: GH) challenge to a core patent underlying Duplex Sequencing. In an Oct. 14, 2026, Final Written Decision on remand from the U.S. Court of Appeals for the Federal Circuit, the PTAB ruled in favor of the University of Washington (UW), determining that Guardant Health failed to establish the unpatentability of any of the 30 challenged claims of U.S. Patent No. 10,760,127. The ‘127 patent is owned by UW and exclusively licensed to TwinStrand.